摘要
目的探讨医院临床分离大肠埃希菌的检测及耐药情况,为医院耐药性监测和临床用药提供指导。方法采用常规方法进行细菌的分离及鉴定;运用VITEK-2全自动细菌分析仪进行细菌的鉴定及药敏分析。结果2007年7-12月共分离出352株大肠埃希菌,产ESBLs菌233株,占66.2%,非产ESBLs菌119株,占33.8%,痰中分离111株,产ESBLs菌89株,非产ESBLs菌22株,尿中分离111株,产ESBLs菌62株,非产ESBLs菌49株;产与非产ESBLs菌株间耐药性具有较大差异,不同来源的菌株对不同的抗菌药物耐药性也表现不同;所有分离菌株可首选哌拉西林/他唑巴坦、头孢替坦、厄他培南,亚胺培南,阿米卡星,呋喃妥因进行治疗。结论医院产ESBLs大肠埃希菌耐药性较为严重(66.2%);医院应加强抗菌药物使用的管理,提高抗菌药物的合理使用,降低细菌耐药率的产生。
OBJECTIVE To explore the drug-resistant situation of clinical isolated Escherichia coli in our hospital from Jun to Dec in 2007, the aim is to offer evidence for drug-resistant monitoring and clinical antibiotics usage in our hospital. METHODS All clinical specimens isolated and cultured from patients were identified by using the automatic microorganism analyzer VITEK-2 as well as bacteria＇s drug susceptibility tests were performed using counterparts panel. RESULTS A total of 352 strains E. coli were isolated. The isolated ratio of extended spectram-β-lactamases （ESBLs） producing E. coli was 66. 2% （233/352）, no ESBLs producing E. coli was 33.8% （119/352）. From them 111 strains E. coli were isolated in sputum and 89 strains were ESBLs producing and 22 strains were no ESBLs producing; 111 strains E. coli were isolated in urine and 62 strains were ESBLs producing and 49 strains were no ESBLs producing. The drug-resistance difference was obvious between them as well as between strains isolated from different sites. Better to select piperacillin/tazobactam, cefotetan, ertapenem, imipenem, amikacin,and nitrofurantoin to cure all isolated E. coli infection. CONCLUSIONS The drugresistance of ESBLs producing E. coli is severe （66.2%） so that hospital administers should strengthen antibiotics usage management and improve antibiotics rational usage, inorder to decrease occurrance of bacterial resistance.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2009年第4期463-465,共3页
Chinese Journal of Nosocomiology
